282 related articles for article (PubMed ID: 29603593)
1. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
2. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
[TBL] [Abstract][Full Text] [Related]
3. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
4. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Daver N; Boumber Y; Kantarjian H; Ravandi F; Cortes J; Rytting ME; Kawedia JD; Basnett J; Culotta KS; Zeng Z; Lu H; Richie MA; Garris R; Xiao L; Liu W; Baggerly KA; Jabbour E; O'Brien S; Burger J; Bendall LJ; Thomas D; Konopleva M
Clin Cancer Res; 2015 Jun; 21(12):2704-14. PubMed ID: 25724525
[TBL] [Abstract][Full Text] [Related]
5. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
6. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
7. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Raetz EA; Borowitz MJ; Devidas M; Linda SB; Hunger SP; Winick NJ; Camitta BM; Gaynon PS; Carroll WL
J Clin Oncol; 2008 Aug; 26(24):3971-8. PubMed ID: 18711187
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Kim SJ; Shin DY; Kim JS; Yoon DH; Lee WS; Lee H; Do YR; Kang HJ; Eom HS; Ko YH; Lee SH; Yoo HY; Hong M; Suh C; Kim WS
Ann Oncol; 2016 Apr; 27(4):712-8. PubMed ID: 26861608
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
10. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
11. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Burke MJ; Kostadinov R; Sposto R; Gore L; Kelley SM; Rabik C; Trepel JB; Lee MJ; Yuno A; Lee S; Bhojwani D; Jeha S; Chang BH; Sulis ML; Hermiston ML; Gaynon P; Huynh V; Verma A; Gardner R; Heym KM; Dennis RM; Ziegler DS; Laetsch TW; Oesterheld JE; Dubois SG; Pollard JA; Glade-Bender J; Cooper TM; Kaplan JA; Farooqi MS; Yoo B; Guest E; Wayne AS; Brown PA
Clin Cancer Res; 2020 May; 26(10):2297-2307. PubMed ID: 31969338
[TBL] [Abstract][Full Text] [Related]
12. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
[TBL] [Abstract][Full Text] [Related]
14. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
15. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
17. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Buchanan GR; Rivera GK; Boyett JM; Chauvenet AR; Crist WM; Vietti TJ
Blood; 1988 Oct; 72(4):1286-92. PubMed ID: 3167209
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Messinger Y; Gaynon P; Raetz E; Hutchinson R; Dubois S; Glade-Bender J; Sposto R; van der Giessen J; Eckroth E; Bostrom BC
Pediatr Blood Cancer; 2010 Aug; 55(2):254-9. PubMed ID: 20582937
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcome of adult acute lymphocytic leukemia with VPD(L) regimen: analysis of prognostic factors.
Park SR; Kim JH; Kim DY; Lee S; Lee SY; Choi IS; Yoon SS; Park S; Kim BG; Kim NK
Korean J Intern Med; 2003 Mar; 18(1):21-8. PubMed ID: 12760264
[TBL] [Abstract][Full Text] [Related]
20. [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
Sato Y; Ito R; Saito T; Suto Y; Tateoka N; Onodera N; Ikeda Y; Ito E; Miyano T; Tachibana N
Rinsho Ketsueki; 1989 Nov; 30(11):1923-30. PubMed ID: 2607611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
